Replies to post #396041 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

The July 22 report says "anti-fungal technology" Brilacidin is not worded in there. Then there's this report that says other then Brilacidin.

On May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC. Some of the preliminary data used in the FCCDC research program had been obtained as part of an earlier collaboration with the Company supported by funding from the National Institutes of Health. Additional payments from FCCDC to the Company may also be made in the future.

The Company and Fox Chase Chemical Diversity Center, Inc. (“FCCDC”) have a collaborative research agreement related to an antifungal drug discovery program. In exchange for a six percent fee tied to all potential future proceeds, the Company granted FCCDC all discovery, intellectual property and commercialization rights related to its share of this joint antifungal drug program which is for a compound other than Brilacidin.*

[PJ007]

I don't believe the compound Basilea handed back is Brilacidin.....Nice try!!!!!

https://www.fiercebiotech.com/biotech/first-hiccup-basileas-anti-infective-strategy-biotech-hands-back-antifungal-9-months-after

[frenchbroad]

Why do I think Brilacidin is a good fit for Basilea objectives? This is a easy question but of course you already know the answer.

*Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy. We have successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole).
Oncology was the second area of Basilea’s research and development activities. In February 2022, Basilea announced to focus on anti-infectives and separate its activities in oncology through transactions with partners specialized in oncology.*
https://www.basilea.com/what-we-do

*A key focus for growing shareholder value will be the in-licensing or acquisition of new anti-infective assets in FY23, as Cresemba’s patents are expected to carry through in major markets to 2027. We believe Basilea has had a strong start to FY23 and anticipate management will continue to consider and potentially negotiate licensing deals.*
https://www.edisongroup.com/research/strong-execution-resulting-in-operating-profitability/31896/

And Brilacidin is an excellent anti-infective and anti-fungal that is looking for a partner. Also anti-virus.
*“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987.*
https://news.temple.edu/news/2021-12-14/michael-l-klein-wins-prestigious-john-scott-award
https://www.google.com/search?client=firefox-b-1-d&q=google+scholar+brilacidin